<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445897</url>
  </required_header>
  <id_info>
    <org_study_id>ABF MP</org_study_id>
    <nct_id>NCT03445897</nct_id>
  </id_info>
  <brief_title>Miltefosine Plus IL Pentamidine for Bolivian CL</brief_title>
  <official_title>Miltefosine Combined With Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Berman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the
      combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120
      ug/mm2 lesion area on days 1, 3, and 5).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the
      combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120
      ug/mm2 lesion area on days 1, 3, and 5). Efficacy and tolerance parameters were assessed.
      Efficacy was assessed at 1, 3, and 6 months post therapy. Tolerance was assessed on each day
      therapy was administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2016</start_date>
  <completion_date type="Actual">February 21, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion size</measure>
    <time_frame>6 months post therapy</time_frame>
    <description>area of lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effects at site</measure>
    <time_frame>days 1, 3, 5 of therapy</time_frame>
    <description>pain, erythema, edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic adverse effects</measure>
    <time_frame>days 1 to 28 of therapy</time_frame>
    <description>gastrointestinal side effects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Leishmaniasis, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miltefosine plus intralesional pentamidine</intervention_name>
    <description>miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  one ulcerative lesion ≤ 900 mm2 in total area,

          -  ≥ 12 years,

          -  parasitologically diagnosed by visualization of amastigotes or culture of
             promastigotes from lesion material,

          -  no antileishmanial therapy in the last 3 months,

          -  no mucosal lesions,

          -  no history of significant concomitant diseases including immunosuppression.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>AB Foundation</investigator_affiliation>
    <investigator_full_name>Jonathan Berman</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

